clinical trial · NCT07265921
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.·phase1·recruiting·n = 232
Advanced Solid CancerSIM0609 for injectiondose expansion of SIM0609 in CRCdose expansion of SIM0609 in GC/GEJC cohortdose expansion of SIM0609 in PDAC cohortdose expansion of SIM0609 in positive other solid tumors
brief summary
This is an open-label,multicenter phase I study to evaluate the safety,Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0609 in Adult Participants with Locally Advanced/Metastatic Solid Tumors
started
Nov 7, 2025
primary completion
Dec 1, 2028
completion
Jun 1, 2029
last updated
Dec 5, 2025
official title
A Phase I First-in-Human, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol